about
Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes.Common variable immunodeficiency: etiological and treatment issues.Toll-like receptor 7 and 9 defects in common variable immunodeficiency.Autoimmunity in common variable immunodeficiency.Toll-like receptor function in primary B cell defects.Loss of retinal function and pigment epithelium changes in a patient with common variable immunodeficiency.Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiencyTACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes.Pathogenesis and treatment of gastrointestinal disease in antibody deficiency syndromes.Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease.The role of toll-like receptors in B-cell development and immunopathogenesis of common variable immunodeficiency.Long-term evaluation of a historical cohort of Iranian common variable immunodeficiency patients.An update on treatment strategies for common variable immunodeficiency.TNFRSF13B/TACI alterations in Greek patients with antibody deficiencies.Unusual case presentations associated with the CD45 C77G polymorphism.Applying T-cell receptor excision circles and immunoglobulin κ-deleting recombination excision circles to patients with primary immunodeficiency diseases.Thymic and bone marrow output in patients with common variable immunodeficiency.TACI mutations and disease susceptibility in patients with common variable immunodeficiency.The B-cell compartment in the peripheral blood of children with different types of primary humoral immunodeficiency.Immunophenotypic Analysis of B Lymphocytes in Patients with Common Variable Immunodeficiency: Identification of CD23 as a Useful Marker in the Definition of the Disease
P2860
Q24673338-21D54EA1-1A0D-4459-B545-E32B7F744F5CQ33377299-B45E0D19-E28D-4768-91AE-BA8F0840C4B9Q33621805-C3A1F2E8-450C-402B-8677-1A7A74D81705Q34013669-19B2DB44-C88C-435B-90D0-363BD93FD443Q34056308-D1D73DF5-01CC-4AD3-B186-2C9447A9A231Q36190430-664C7A38-EEE0-455D-A9C8-8412F0D27D4FQ36302313-679E339B-93DB-473A-A274-C3D328C9566AQ36539053-99E10682-B44B-4767-A466-719FFCC1D3CBQ36823203-EB2C8363-1318-4236-8372-BB78FA4A890DQ37441210-2BF4C274-B5E2-4475-9409-73A5CDC41506Q37478243-68D863C5-3D9D-45EE-A5C0-DA334C388F73Q38665495-00004191-4BD9-4159-AD06-345B8912A9A7Q41737545-9ECBD4FD-DE8A-4791-B88B-5CE9EA4A2EFCQ44024797-55A0632C-2883-413A-8B04-73D1E5202A84Q45878656-1D9FB0AB-0E3A-4B55-9DA1-E3DE2BB45407Q50075674-794DF854-CF88-47F4-ACF2-B3B70A4FD288Q50787758-7316FFA8-F836-4263-A02D-F6CC10CB02E7Q51012780-5AED528C-654E-4431-9DB8-EDA654A8CB5BQ51827117-B016FC3C-3D90-4E16-A090-8E7380436809Q51957549-C704D295-F0B7-4A36-A2BA-4F9F54053127Q58996149-D05F6574-3828-451C-A17D-4BA578A54055
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Tackling the heterogeneity of CVID.
@ast
Tackling the heterogeneity of CVID.
@en
type
label
Tackling the heterogeneity of CVID.
@ast
Tackling the heterogeneity of CVID.
@en
prefLabel
Tackling the heterogeneity of CVID.
@ast
Tackling the heterogeneity of CVID.
@en
P1476
Tackling the heterogeneity of CVID.
@en
P2093
Klaus Warnatz
Sigune Goldacker
P304
P356
10.1097/01.ALL.0000191888.97397.B3
P577
2005-12-01T00:00:00Z